Goldman Sachs to make performance-based job cuts in April, source says

Small, targeted staff cuts are planned at Goldman Sachs in April, specifically among underperforming employees and not part of its regular 1-3% annual 'strategic resource assessment'. The firm says this is routine headcount management; the move sits alongside a broader corporate trend of job trimming amid rising AI adoption. Peer Morgan Stanley recently cut about 3% of its workforce (~2,500 roles), underscoring sector-wide efficiency moves rather than firm-specific distress.

Analysis

When a large bank pursues surgical headcount trimming rather than broad layoffs, the near-term P&L impact tends to be disproportionately positive for margins while leaving origination capacity intact. A 0.5–1.0% reduction in fully loaded labor costs at a major bank plausibly converts into low‑hundreds of millions of annual pre‑tax savings — enough to move quarterly EPS and return‑on‑equity metrics by measurable single‑digit percentage points without materially degrading senior coverage ratios.

Second‑order winners are boutique advisory shops and specialized trading desks that can pick up junior coverage responsibilities and fee pools displaced by conservative incumbent hiring, while vendors focused on recruitment and contingent staffing see revenue erosion. The speed and visibility of AI adoption are the wild card: meaningful productivity gains can compress ongoing FTE needs over 12–36 months, but they also raise operational execution risk if cuts concentrate in client‑facing roles (origination and relationship management), which would show up as declining revenue per head over successive quarters.

Consensus is leaning negative on headline cost actions, but that may be overstated for banks that execute surgical reallocations well. The path for outperformance is measurable — 1–3 quarters of higher margins followed by stabilization of deal flow. Key near‑term indicators to watch are quarterly revenue per employee, IB backlog trends, and sequential compensation expense as a percent of revenue; these will separate cosmetic from value‑creative moves within 1–4 quarters.

Key Decisions for Investors

• Pair trade (6 months): Long GS equity / Short MS equity, 1:1 size equalized by dollar exposure. Target relative outperformance of +10–15% in 3–6 months; set a stop if the pair moves against you by 6% absolute. Rationale: surgical efficiency upgrades should lift GS margins faster than a bank already through larger cuts that faces execution and origination risk.
• Options trade (6 months, defined risk): Buy GS 6‑month call spread (buy 10% OTM, sell 25% OTM). Size 0.5% NAV. Max loss = premium; target 2–3x payoff if GS rallies 10–20% as markets reward margin improvement.
• Hedged short (3–6 months): Buy MS 4‑6 month put spread (buy ~7–10% OTM, sell ~15–20% OTM). Size 0.5% NAV. This caps downside while capturing >3x payoff if market reprices MS for execution risk or slower origination flow over the next 1–2 quarters.
• Trigger-based scaling: If quarterly metrics show revenue per head rising and comp/revenue down by ≥100bps sequentially, add to GS exposure (up to an incremental 0.5% NAV). Conversely, if IB backlog falls >10% QoQ or compensation as % of revenue increases, reduce GS and take profits on the pair.